Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Song, Zi Ye ^a   Yamasaki, Ryo ^b   Kawano, Yuji ^a   Sato, Shinya ^a   Masaki, Katsuhisa ^a   Yoshimura, Satoshi ^a   Matsuse, Dai ^a   Murai, Hiroyuki ^a   Matsushita, Takuya ^a   Kira, Jun Ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FINGOLIMOD; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD T LYMPHOCYTE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; CASE CONTROL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928692825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124923     Document Type: Article

References (37)

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007; 8: 913-919. PMID: 17712344
2. Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology. 2011; 76 (Suppl 3): S9-14. doi: 10.1212/WNL.0b013e31820d9507 PMID: 21339490
3. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33: 91-101. doi: 10.1097/WNF.0b013e3181cbf825 PMID: 20061941
4. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005; 2: 439-48. PMID: 16426494
5. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745-763. PMID: 15032595
6. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008; 71: 1261-1267. doi: 10.1212/01.wnl.0000327609.57688.ea PMID: 18852441
7. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australia. Am J Transplant. 2006; 6: 2912-21. PMID: 17061999
8. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010; 75: 403-410. doi: 10.1212/WNL.0b013e3181ebdd64 PMID: 20592255
9. Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, et al. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol. 2014; 268: 95-98. doi: 10.1016/j.jneuroim.2014.01.008 PMID: 24507619
10. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol. 2008; 180: 7948-7957. PMID: 18523258
11. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58: 840-846. PMID: 16283615
12. Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain. 2007; 130: 1206-1223. PMID: 17439988
13. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler. 2009; 15: 834-847. doi: 10.1177/1352458509104595 PMID: 19465451
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33: 1444-1452. PMID: 6685237
15. Poser S, Ritter G, Bauer HJ, Grosse-Wilde H, Kuwert EK, Raun NE. HLA-antigens and the prognosis of multiple sclerosis. J Neurol. 1981; 225: 219-221. PMID: 6167687
16. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler. 2012; 18(9):1269-77. doi: 10.1177/1352458511435984 PMID: 22354739
17. Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin-4 antibody status. J Neurol Neurosurg Psychiatry. 2013; 84: 29-34. doi: 10.1136/jnnp-2012-302925 PMID: 23038741
18. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler. 2009; 15: 834-847. doi: 10.1177/1352458509104595 PMID: 19465451
19. Cui YW, Kawano Y, Yamasaki R, Shi N, Masaki K, Isobe N, et al. Decreased CCR2 and CD62L expressions on peripheral blood classical monocytes in amyotrophic lateral sclerosis. Clin Exp Neuroimmunol. 2014; 5: 92-96.
20. Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12-months: results of a phase 2 observational extension. BMC Neurol. 2014; 14: 21. doi: 10.1186/1471-2377-14-21 PMID: 24475777
21. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009; 65: 499-509. doi: 10.1002/ana.21652 PMID: 19475668
22. Chiba K, Kataoka H, Seki N, Shimano K, Koyama M, Fukunari A, et al. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2011; 11: 366-372. doi: 10.1016/j.intimp.2010.10.005 PMID: 20955831
23. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler.2012; 18: 113-115. doi: 10.1177/1352458511431973 PMID: 22146605
24. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012; 18: 1650-1652. doi: 10.1177/1352458512463768 PMID: 23100527
25. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012; 79: 2000-2003. doi: 10.1212/WNL.0b013e3182735cb3 PMID: 23035065
26. Ishizu T, Osoegawa M, Mei F-J, Kikuchi H, Tanaka M, Takakura Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005; 128: 988-1002. PMID: 15743872
27. Tanaka M, Matsushita T, Tateishi T, Ochi H, Kawano Y, Mei FJ, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology. 2008; 71: 974-981. doi: 10.1212/01.wnl.0000326589.57128.c3 PMID: 18809833
28. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLOS ONE. 2013; 8(4): e61835. doi: 10.1371/journal.pone.0061835 PMID: 23637915
29. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol. 2001; 119(2): 297-305. PMID: 11585633
30. Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van Lier RA. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler. 2001; 7(3): 145-50 PMID: 11475436
31. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987; 1(8538): 893-895. PMID: 2882294
32. Ochi H, Mei F-J, Osoegawa M, Minohara M, Murai H, Taniwaki T, et al. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J Neurol Sci. 2004; 222: 65-73. PMID: 15240198
33. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol. 2010; 88: 624-631. doi: 10.1038/icb.2010.53 PMID: 20421880
34. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17 and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009; 183: 7169-7177. doi: 10.4049/jimmunol.0901906 PMID: 19890056
35. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med. 2009; 206: 1653-1660. doi: 10.1084/jem.20090246 PMID: 19596803
36. Putheti P, Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4 +CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol. 2003; 144: 125-131. PMID: 14597106
37. Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol. 1995; 2: 249-252. PMID: 7697540